Search NASA⌕ Search

SEARCH · Search NASA

Results for “Medical Supply”

Search indexed NASA NTRS and DOE OSTI research on propulsion, heat transfer, battery materials and energy systems. Follow report and document links to the original sources.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 55 records · Page 3
All sourcesNASA NTRSDOE OSTI
NASA NTRSDate not supplied

Investigating the Applications of In-Situ Resource Utilization for Future Crewed Mars Missions

Several advancements are necessary before humans can safely explore Mars. One emerging strategy is In-Situ Resource Utilization (ISRU): the process of extracting raw materials found onsite and converting them into usable products to ensure a constant flow of vital resources and greatly reduce overall mission cost. Scientists must confirm the presence and accessibility of these resources for future crewed missions. Our team investigated the feasibility of ISRU in NE Syrtis, a region of Mars with varied geology, mineralogy, and hydrological history. NE Syrtis has abundant subsurface water and a diverse suite of mineral deposits including olivine, phyllosilicates, sulfates, and carbonates–all of which can be leveraged for fuel, medical supplies, and/or construction materials. We conceptualized a joint rover and helicopter expedition to analyze and sample these minerals over a two-year primary mission using Java Mission-planning and Analysis for Remote Sensing (JMARS), Planetary Data Systems (PDS), and Computer-Aided Design (CAD). We plotted a strategic traverse to regions of interest identified from remote sensing data and planned operations at each target. Our mission aimed to prepare for human presence on Mars by demonstrating the utility and viability of ISRU-focused operations.

Zahra M. Ronizi↗
NASA NTRSDate not supplied

Ground Testing of an Oxygen Concentrator in a Simulated International Space Station (ISS) Cabin Environment

The method for supplying medical oxygen to respiratorily-compromised astronauts on the International Space Station (ISS) and in future Orion missions consists of drawing oxygen from high pressure oxygen tanks. An Oxygen Concentrator Module (OCM) is a device that pulls in ambient air and separates out the nitrogen, resulting in a high concentration oxygen source. This technology has the potential to eliminate resupply and oxygen-enrichment issues associated with using high pressure oxygen tanks and become an alternative technology to support medical oxygen operations for future exploration missions. In this study, we test the long-term performance of a Commercial Off-the-Shelf (COTS) OCM in a simulated ISS cabin environment. Humidified air, carbon dioxide, and fifteen representative trace contaminants are continuously injected through a enclosed test chamber where the OCM is challenged. This study included the first successful demonstration of the Trace Gas Injection System (TGIS), which reliably and continuously produced ISS levels of trace contaminants, carbon dioxide, and humidity in an enclosed environment. The TGIS is a new and unique ground capability with significant implications for Test Readiness Level (TRL) advancement of COTS items and Government Furnished Equipment (GFE). This study demonstrated that the tested OCM reliably delivers enriched oxygen mostly at desired performance specifications. This study also demonstrated that the OCM does not inadvertently concentrate trace gases in its oxygen product stream, as detectable concentrations of trace contaminants in the oxygen product stream were at all times below the simulated ISS levels.

medical oxygen↗
NASA NTRSDate not supplied

The Influence of Viability, Independence, and Self-Governance on Trust and Public Acceptance of Uncrewed Air Vehicle Operations

Trust is expected to be a critical construct that drives successful use of advanced air mobility (AAM) technologies. As yet, though, the role of trust in human-autonomy interaction is underexplored. Kaber (2018) argues that autonomy requires the highest level of three independent dimensions -- viability, independence, and self-governance. The present study examined whether trust varies across the three dimensions of autonomy under varying levels of risk. Participants in the high-risk group read a series of vignettes on a drone that delivers medical supplies over a city where the current study was conducted. Participants in the low-risk group read a series of vignettes on a drone that delivers fast food over a fictitious city. Each vignette described a drone that is either autonomous (i.e., possesses all dimensions) or automated (i.e., one of the dimensions is compromised). Results imply that the three dimensions of autonomy do not equally influence human-technology trust and behavior.

Advanced Air Mobility↗
NASA NTRSDate not supplied

Ground Testing of an Oxygen Concentrator in a Simulated International Space Station (ISS) Cabin Environment

The method for supplying medical oxygen to respiratorily-compromised astronauts on the International Space Station (ISS) and in future Orion missions consists of drawing oxygen from high pressure oxygen tanks. An Oxygen Concentrator Module (OCM) is a device that pulls in ambient air and separates out the nitrogen, resulting in a high concentration oxygen source. This technology has the potential to eliminate resupply and oxygen-enrichment issues associated with using high pressure oxygen tanks and become an alternative technology to support medical oxygen operations for future exploration missions. In this study, we test the long-term performance of a Commercial Off-the-Shelf (COTS) OCM in a simulated ISS cabin environment. Humidified air, carbon dioxide, and fifteen representative trace contaminants are continuously injected through an enclosed test chamber where the OCM is challenged. This study included the first successful demonstration of the Trace Gas Injection System (TGIS), which reliably and continuously produced ISS levels of trace contaminants, carbon dioxide, and humidity in an enclosed environment. The TGIS is a new and unique ground capability with significant implications for Test Readiness Level (TRL) advancement of COTS items and Government Furnished Equipment (GFE). This study demonstrated that the tested OCM reliably delivers enriched oxygen mostly at desired performance specifications. This study also demonstrated that the OCM does not inadvertently concentrate trace gases in its oxygen product stream, as detectable concentrations of trace contaminants in the oxygen product stream were at all times below the simulated ISS levels.

medical oxygen↗
NASA NTRSDate not supplied

Combinatorial Auction-Based Strategic Deconfliction of Federated UTM Airspace

Unmanned Aerial Vehicles (UAVs) have become commonly used to perform a wide range of commercial activities such as cinematography and medical supply delivery. Consequently, regulators have become interested in designing UAV Traffic Management systems (UTMs) to coordinate UAV traffic among a collection of UAV operators. One framework which has been recently proposed for a UTM system is a combinatorial auction. In this framework, airspace is modelled as a 4D grid of space-time cells. UAV operators bid on cells which collectively form paths for their UAVs. Ideally, an airspace auction should reveal information about the current price of flight paths to bidders, allowing bidders to identify and bid on a select number of paths instead of placing as many bids as possible in the hopes of stumbling on a cheap path. Revealing too much information, however, can allow bad actors to place bids which are intended not to win but to raise the price that a rival bidder must pay. We address these twin challenges with a new information revelation framework which provides bidders with wide-ranging pricing information while suppressing bad actors. We evaluate our framework on scenarios based on a Japan Aerospace Exploration Agency (JAXA) case study and find that it can scale to thousands of bids.

Christopher J C Leet↗
NASA NTRS2023

Automated Medical Inventory System (AMIS) TechPort Entry

The current medical inventory paradigm on the International Space Station (ISS) requires crew to report use of medications and supplies to be manually decremented by ground teams. This method is not only tedious and time consuming for both the crew and ground teams but also results in inaccuracies in location and availability of medical supplies over time. Fortunately, the ISS is frequently resupplied by cargo launches and crew expeditions, and an accurate inventory count is less critical. However, for exploration missions, resupply will be greatly limited or unavailable entirely, and increasing communication latency will impair crew-ground communications. On longer missions, with large medical systems and time constrained crew, NASA needs a method of accurately managing medical inventory without reliance on ground teams and with as little crew time and effort as possible. The Exploration Medical Integrated Product Team (XMIPT) project called Medical Exploration Development and Implementation Scoping (MEDIScope) prepared a concept of operations and preliminary requirements for an Automated Medical Inventory System (AMIS) and completed a market survey and trade study of potential inventory management technologies in partnership with the market research firm, yet2. The products from the MEDIScope effort, including the market survey results, preliminary functional requirements and a concept of operations, have been handed off to a development team at Glenn Research Center (GRC) and ZIN Technologies for technology maturation. In the development phase, the AMIS team will finalize system requirements, down select technologies, integrate with a future exploration Crew Health and Performance Integrated Data Architecture, and conduct design reviews. The project will culminate in an ISS technical flight demonstration in FY27.

MEDIScope↗
NASA NTRS2003

A Robot to Help Make the Rounds

This paper presents a discussion on the Pyxis HelpMate SecurePak (SP) trackless robotic courier designed by Transitions Research Corporation, to navigate autonomously throughout medical facilities, transporting pharmaceuticals, laboratory specimens, equipment, supplies, meals, medical records, and radiology films between support departments and nursing floors.

Source record↗
NASA NTRS2023

Exploring the Complexities of Drug Formulation Selection, Storage, and Shelf-Life for Exploration Spaceflight

Medications have been a part of space travel dating back as far as the Apollo missions. Currently, medical kits aboard the ISS contain medications and supplies to help crew members cope with a variety of possible medical events. NASA reported that 1,867 medical events occurred from 1981 to 1998 on space shuttle flights, STS-1 to STS-89; 498 out of the 508 crewmembers on those flights reported experiencing a medical event other than space motion sickness. In 2000, the Institute of Medicine (IOM) convened a committee of experts, Committee on Creating a Vision for Space Medicine during Travel beyond Earth Orbit, to examine the issues surrounding astronaut health and safety for long duration space missions. The primary theme of the committee’s final report is that there is not enough known about the risks to human health during long-duration missions beyond Earth’s orbit and ways to effectively mitigate those risks in an environment of deep space. In 2014, the IOM convened the Committee on Ethics Principles and Guidelines for Health Standards for Long Duration and Exploration Spaceflights and released a report emphasizing the importance of prevention, mitigation, and treatment of major risks to human health during exploration spaceflight. NASA’s Human Research Program has organized five distinct categories of spaceflight hazards summarized by the acronym “RIDGE” (Space Radiation, Isolation and Confinement, Distance from Earth, Gravity fields, and Hostile/Closed Environments) that astronauts may encounter during exploration spaceflight. From those hazards, NASA further derived 30 of the most critical human health and performance risks, including limits to medical care resulting from pharmaceutical degradation. As we prepare for more distant exploration missions to Mars and beyond, risk management planning for astronaut healthcare should include the assembly of a medication formulary that is comprehensive enough to prevent or treat anticipated medical events, remains safe and chemically stable, and retains sufficient potency to last for the duration of the mission. The present editorial will summarize the current state of knowledge regarding innovative formulary optimization strategies, pharmaceutical stability assessment techniques, and storage and packaging solutions that could enhance drug safety and efficacy for future exploration spaceflight missions.

drug degradation risk assessment↗
NASA NTRS2023

Intravenous Fluid Generation Mini (IVGEN Mini) Summary and Related Research

This paper assists the ongoing effort to support NASA Glenn’s mission and its Human Research Program (HRP) core competency by investigating a technology demonstration to mitigate human health and performance risks during space exploration. Crew health and performance are critical to successful human exploration beyond low Earth orbit. Four hundred forty-two medical conditions have been identified and may present and require treatment during long-duration space exploration missions. One hundred fifteen out of four hundred forty-two identified medical conditions would require medical fluid treatment, generating a need for an on-demand or continuous supply of medical fluid. Intravenous Fluid Generation Mini (IVGEN Mini) is a technology demonstration designed to demonstrate a water purification and pharmaceutical mixing system that can make intravenous (IV) fluid in microgravity and builds on the success of the original Intravenous Fluid Generation for Exploration Missions (IVGEN) experiment, which flew on the ISS in March 2010. IVGEN Mini seeks to increase the Technology Readiness Level (TRL) and the overall function of the original IVGEN experiment to reduce the dependence of a needed medical consumable and streamline the size of the device and process to generate IV fluid IVGEN Mini is funded by the Advanced Exploration Systems (AES) directorate via the Exploration Medical Integrated Product Team (XMIPT) as a part of their mission to advance exploration medical technologies to benefit the overall health and safety of crews for beyond low Earth orbit space missions. This paper discusses a collection of related research topics such as microgravity fluid mixing and studying past efforts of IV fluid usage in extreme environments to aid IVGEN Mini project scientists in developing the IVGEN Mini technology.

iv generation↗
NASA NTRSDate not supplied

Challenges, Considerations, and Opportunities for Exercise and Medical Accommodation Inside a Small Pressurized Rover

Pressurized Rovers (PR) can enable crew to explore away from a lander or surface habitat at distances not possible on foot or even in unpressurized rovers. Sustaining crew for multiple days, they can rove for weeks, independent of other surface elements. Because these are essentially mobile habitats, it is critical that they provide sufficient volume to accommodate the exercise and medical systems to maintain human health in remote, low gravity environments such as the Moon and Mars. This is an area of extensive unknowns as requirements have not yet been developed for exercise or medical systems in pressurized rovers. Yet they must be considered in vehicle sizing studies as they are significant volume drivers, requiring allocation for stowed and deployed hardware inside the rover cabin. Previously flown spacecraft have allocated varying amounts of volume based on the expected crew mission and the state of the art in these systems. NASA-STD-3001 provides high-level requirements for standards of medical care and exercise capabilities. Crew injuries are possible both inside the cabin and on extravehicular activities (EVA), therefore requiring medical capability. Exercise countermeasures are needed to counteract the debilitating effects of lowered gravity. This may include both reconditioning following a lengthy microgravity transit as well as ongoing countermeasures against the effect of low surface gravity. The NASA reference concept for the PR dates back to the Constellation Program and prototypes have been extensively tested in NASA’s Desert Research and Technology Studies (DRATS) program as well as at the NASA Johnson Space Center. The PR cabin is designed to accommodate two crewmembers and is subdivided into a forward cockpit area and a main body for crew habitation. EVAs are accomplished by transitioning through suit ports in the aft bulkhead into spacesuits. While no exercise devices have been developed for the PR, some have been prototyped and demonstrated in DRATS analog missions. A cycle ergometer performed reasonably well in DRATS testing as an aerobic exercise device and recent analysis work has theorized that a combination aerobic and resistive device could be packaged into a form factor similar to the DRATS ergometer. It is therefore suitable for use as an initial volumetric placeholder. No sensorimotor devices have been considered for the PR to aid in adaptation to surface gravity. However, there are commercially available treadmills that at minimum represent examples of the type of exercise system that could potentially be used for such a purpose. A combination of field test data, analysis, and CAD modeling will be used to perform a first pass assessment of whether these exercise devices can be stowed and deployed within the PR. Medical inventories from the International Space Station will be used as a volume placeholder for the PR medical system. A configuration will be discussed for medical deployment, including positioning of caregiver, patient, and medical equipment / supplies.

Pressurized Rover↗
NASA NTRS2012

Advances in Nanotechnology for Efficacious and Stable Formulation Development

Current operational medical kits aboard the International Space Station (ISS) include an array of medications intended for the treatment of minor ambulatory care symptoms, first aid, and basic life support. All medications contained in the flight kits are commercially available off-the-shelf formulations used for treatment of illnesses on Earth. However, transport and stowage of supplies including medications for space missions are exposed to adverse environmental conditions and extended shelf-life demands. Proposed missions to Mars and near-Earth objects such as asteroid 1999 AO10 will present crew health risk that is different both quantitatively and qualitatively from those encountered on ISS missions. Few drug options are available at the present time for mitigation of crew health risk of planned space exploration missions. Alternatives to standard oral formulations that include sustained and targeted delivery technologies for preventive healthcare in space will be a welcome addition to the space formulary and may include controlled release topical, sub-cutaneous, intranasal and inhalation dosage forms. An example of such a technology development endeavor can be nanotechnology-based multi-stage drug cocktail and vaccine delivery systems. Nanostructures also have the ability to protect drugs encapsulated within them from physiologic degradation, target their delivery with sustained release and are suitable for per oral routes of administration. The use of nanostructures such as polymeric nanoparticles offers a non-invasive approach for penetrating the blood brain barrier. Finally, nanotechnology offers great potential for the development of safe and efficacious drug delivery systems for preventive health care in space and on Earth.

Putcha, Lakshimi↗
NASA NTRS2014

Stability Analysis of ISS Medications

It is known that medications degrade over time, and that extreme storage conditions will hasten their degradation. The temperature and humidity conditions of the ISS have been shown to be within the ideal ranges for medication storage, but the effects of other environmental factors, like elevated exposure to radiation, have not yet been evaluated. Current operational procedures ensure that ISS medications are re-stocked before expiration, but this may not be possible on long duration exploration missions. For this reason, medications that have experienced long duration storage on the ISS were returned to JSC for analysis to determine any unusual effects of aging in the low- Earth orbit environment. METHODS Medications were obtained by the JSC Pharmacy from commercial distributors and were re-packaged by JSC pharmacists to conserve up mass and volume. All medication doses were part of the ISS crew medical kit and were transported to the International Space Station (ISS) via NASA's Shuttle Transportation System (Space Shuttle). After 568 days of storage, the medications were removed from the supply chain and returned to Earth on a Dragon (SpaceX) capsule. Upon return to Earth, medications were transferred to temperature and humidity controlled environmental chambers until analysis. Nine medications were chosen on the basis of their availability for study. The medications included several of the most heavily used by US crewmembers: 2 sleep aids, 2 antihistamines/decongestants, 3 pain relievers, an antidiarrheal and an alertness medication. Each medication was available at a single time point; analysis of the same medication at multiple time points was not possible. Because the samples examined in this study were obtained opportunistically from medical supplies, there were no control samples available (i.e. samples aged for a similar period of time on the ground); a significant limitation of this study. Medications were analyzed using the HPLC/MS methods described in the United States Pharmacopeia (USP) to measure the amount of intact active ingredient, identify degradation products and measure their amounts. Some analyses were conducted by an independent analytical laboratory, but certain (Schedule) medications could not be shipped to their facility and were analyzed at JSC. RESULTS Nine medications were analyzed with respect to active pharmaceutical ingredient (API) and degradant amounts. Results were compared to the USP requirements for API and degradants/impurities content for every FDA-approved medication. One medication met USP requirements at 5 months after its expiration date. Four of the nine (44% of those tested) medications tested met USP requirements up to 8 months post-expiration. Another 3 medications (33% of those tested) met USP guidelines 2-3 months before expiration. One medication, a compound classed by the FDA as a dietary supplement and sometimes used as a sleep aid, failed to meet USP requirements at 11 months post-expiration. CONCLUSION Analysis of each medication at a single time point provides limited information on the stability of a medication stored in particular conditions; it is not possible to predict how long a medication may be safe and effective from these data. Notwithstanding, five of the nine medications tested (56%) met USP requirements for API and degradants/impurities at least 5 months past expiration dates. The single compound that failed to meet USP requirements is not regulated as strictly as prescription medications are during manufacture; it is unknown if this medication would have met the requirements prior to flight. Notably, it was the furthest beyond its expiration date. Only more comprehensive analysis of flight-aged samples compared to appropriate ground controls will permit determination of spaceflight effects on medication stability.

Wotring, V. E.↗
NASA NTRS2021

Exploration Medical Capability Clinical Decision Support System Concept of Operations

The Clinical Decision Support (CDS) project supports the Exploration Medical Capability (ExMC) Element of the Human Research Program (HRP). Specifically, the CDS project addresses the ExMC gap, Medical-701: Enhance medical capabilities within an exploration medical system. For long-duration, deep space missions, computational and data resources will play an important role in maintaining crew health, wellness and performance where the crew will need to be more self-reliant as we enter a new era in space exploration to return to the moon and explore Mars. These ambitious goals will require significant change in in-flight medical care due to constraints on mass, volume, power, crew time, skills reduction over time and medical evacuation capabilities. These constraints make it absolutely necessary to develop transformative solutions using new technologies. Unlike the current paradigm for crew health in low-Earth orbit missions that rely on constant communication with Mission Control, the deep space missions will experience communication delays and possibly, no communications for finite periods of time. Hence, crew health management will benefit from analytics’ capabilities to augment decision support. A comprehensive, multi-functional on-board clinical decision support system (CDSS) will help crews assess and diagnose conditions, decide appropriate responses, and guide the provision of tailored and evidence-based treatments, while reflecting contextual factors and constraints. The context may include present and historical data, viable diagnostic equipment, available supplies and medications, and vehicle and environmental health. Communication time with ground-based personnel is delayed or non-existent during significant portions of the mission so the crew will need to autonomously respond to health, performance and medical situations, particularly those that are unplanned. The CDSS must also provide additional capabilities as complex as training for an emergency situation while augmenting non-expert practitioner skillsets if the Crew Medical Officer (CMO) is incapacitated, and as routine as facilitating delayed communication with flight surgeons on the ground. The CDSS must connect complex issues involving health, wellness, task performance and environmental domains. Furthermore, CDSS functionality will focus on semi-autonomous and autonomous decision-making by the crew that is necessary to address challenges in executing a self-contained medical system that enables health care without assistance from ground clinical experts. The document, ExMC CDSS Architecture Recommendation, (HRP- 48032) establishes a description of the envisioned CDSS architecture. The analytics, descriptive or advanced, contained in a CDSS will interface with the integrated crew health and performance architecture that provides the appropriate data sets. The aim of the CDS project is to develop requirements for a CDSS through a series of test-bed prototype developments and demonstrations.

HRP↗
DOE OSTI2021

Inactivation of Human Coronavirus by FATHHOME’s Dry Sanitizer Device: Rapid and Eco-Friendly Ozone-Based Disinfection of SARS-CoV-2

The pandemic of SARS-CoV-2/COVID-19 was reported in December 2019 in Wuhan, China. Pertaining to its high transmissibility and wide host adaptability, this unique human coronavirus spread across the planet inflicting 115 million people and causing 2.5 million deaths (as of March 3rd, 2021). Limited or negligible pre-existing immunity to multiple SARS-CoV-2 variants has resulted in severe morbidity and mortality worldwide, as well as a record-breaking surge in the use of medical-surgical supplies and personal protective equipment. In response to the global need for effective sterilization techniques, this study evaluated the virucidal efficacy of FATHHOME’s self-contained, ozone-based dry-sanitizing device, by dose and time response assessment. We tested inactivation of human coronavirus, HCoV-OC43, a close genetic model of SARS-CoV-2, on porous (N95 filtering facepiece respirator/FFR) and nonporous (glass) surfaces. We started our assays with 20 ppm-10 min ozone exposure, and effectively reduced 99.8% and 99.9% of virus from glass and N95 FFR surfaces, respectively. Importantly, the virus was completely inactivated, below the detection limit (over 6-log10 reduction) with 25 ppm-15 min ozone exposure on both tested surfaces. As expected, a higher ozone exposure (50 ppm-10 min) resulted in faster inactivation of HCoV-OC43 with 100% inactivation from both the surfaces, with no residual ozone present after completion of the 5-min post exposure recapture cycle and no measurable increase in ambient ozone levels. These results confirmed that FATHHOME’s device is suitable for rapid decontamination of SARS-CoV-2- from worn items, frequently touched items, and PPE including N95 FFRs, face shields, and other personal items. View Full-Text

59 BASIC BIOLOGICAL SCIENCES↗
NASA NTRS1983

Regulating Oxygen Pressure Safely

Pressure regulator for oxygen allows gas flow shut off on low-pressure (outlet) side rather than high-pressure (inlet) side. In modified pressure regulator initial rush of oxygen occurs in second stage rather than first stage of pressure reduction. Large volume of second stage prevents excessive heating of gas. High-pressure source remains on, and first stage reamins pressurized at all times. New regulator reduces danger of fire in aircraft and in medical oxygen supplies.

Simons, C.↗
NASA NTRS2024

SupportU: Smart UAS Program for the Population by Offering Resources and Tools to the Unhoused

Global warming, challenging economic conditions, the opioid epidemic, and other widespread problems, have impacted people globally, particularly over the past several years. Preventable diseases like the common cold and the effects of heat stroke have become increasingly prevalent due to these issues. It is estimated that 150 million people of the world’s population are unhoused globally, with many dwelling in unsafe and unsanitary conditions while lacking access to basic hygienic items and other essentials. Unsanitary conditions coupled with this lack of access exacerbates and prolongs health problems and harms quality of life. Traditional methods of aid, such as homeless shelters and meal programs, face numerous challenges such as having limited reach and resources. To address these problems, the Smart UAS Program for the Population by Offering Resources and Tools to the Unhoused (SUPPORT U) utilizes Uncrewed Aircraft Systems (UAS) to deliver resources to the unhoused and those in need of basic aid, prior to and during extreme temperature conditions, and after natural disasters in rural, suburban, and urban areas. The UA is envisioned to be an autonomous aircraft capable of efficiently distributing essential supplies, including blankets, water, food, and medicine. The UAS fleet relies on advanced navigation and communication technologies to accurately identify unhoused people and efficiently and safely distribute materials to them. This will be done through a machine learning algorithm. By focusing on identified “homeless clusters”, places where unhoused individuals are concentrated, the UAS network increases access to critical resources, thereby helping to mitigate some of the external risks to the health of unhoused individuals. The UA can also be used during crises, such as by transporting supplies to medical tents that are stationed in difficult-to-reach areas suffering from natural disasters.

Samuel Beard↗
NASA NTRS1991

Shuttle Orbiter medical system equipment/supplies evaluation

The effectivity was evaluated in zero gravity of several medical equipment and supply items flown in the Shuttle Orbiter Medical System (SOMS). Several procedures listed in Medical Operations Medical Checklist, JSC 1732 were also evaluated. Several items were drawn out of the kits and tested on the KC-135. In two different flights, the following elements were examined: (1) measuring IV flow (drip chamber, one way flow valve, and air/fluid separator); (2) chemstrip protocol for urine analysis in zero-gravity; and (3) tamper resistant seals for injectable medications.

Maidlow, Kristin↗